Did Earnings And Buybacks Just Shift United Therapeutics (UTHR) Investment Narrative?

Simply Wall St.09:18

United Therapeutics reported third quarter 2026 sales of US$832.5 million versus US$799.5 million a year earlier, while net income and diluted EPS from continuing operations declined compared with the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2683547865?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-13 09:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2683547865","market":"hk","top_or_hot":-1,"title":"Did Earnings And Buybacks Just Shift United Therapeutics (UTHR) Investment Narrative?","media":"Simply Wall St.","content":"<div>\n<p>United Therapeutics reported third quarter 2026 sales of US$832.5 million versus US$799.5 million a year earlier, while net income and diluted EPS from continuing operations declined compared with the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/did-earnings-and-buybacks-just-shift-united-therapeutics-uth\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Did Earnings And Buybacks Just Shift United Therapeutics (UTHR) Investment Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDid Earnings And Buybacks Just Shift United Therapeutics (UTHR) Investment Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-13 09:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/did-earnings-and-buybacks-just-shift-united-therapeutics-uth><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>United Therapeutics reported third quarter 2026 sales of US$832.5 million versus US$799.5 million a year earlier, while net income and diluted EPS from continuing operations declined compared with the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/did-earnings-and-buybacks-just-shift-united-therapeutics-uth\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/did-earnings-and-buybacks-just-shift-united-therapeutics-uth","article_id":"2683547865","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/did-earnings-and-buybacks-just-shift-united-therapeutics-uth","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2683547865","pubTimestamp":1794532693,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 13, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗"},"translate_title":"盈利和回购是否改变了联合治疗公司 (UTHR) 的投资叙事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1.5},"content_text":"United Therapeutics reported third quarter 2026 sales of US$832.5 million versus US$799.5 million a year earlier, while net income and diluted EPS from continuing operations declined compared with the prior period. The drug maker also completed a sizeable share repurchase program, buying back 3,523,789 shares for about US$2.0b, which materially reduced its share count. Next, the focus shifts to how United Therapeutics' investment narrative is shaped by EPS pressure alongside this completed US$2.0b buyback.  Spot opportunities that echo the EPS pressure and capital returns story at United Therapeutics by scanning our curated list of 20 high quality undiscovered gems with similar fundamentals under the radar. AdvertisementWhat Is United Therapeutics' Investment Narrative? Owning United Therapeutics is really a bet on disciplined execution in complex, high-need diseases. The latest quarter shows that sales were close to flat year to date while earnings per share from continuing operations moved lower, so near term, this is less a top line growth story and more about how efficiently the portfolio is run. For a shareholder, the belief has to be that management can keep demand and pricing for pulmonary arterial hypertension therapies resilient enough to support ongoing research in organ platforms without letting capital intensity erode returns. The recently completed US$2.0b buyback, which retired 8.13% of the share base, sits right inside that narrative. Shrinking the float can soften the optical impact of EPS pressure, although the latest quarter shows that operational headwinds can still dominate the earnings line. That makes upcoming data readouts, regulatory milestones and competitive responses around Tyvaso and treprostinil franchises the key near term swing factors, while the organ and xenotransplantation pipeline stays more of a long game. Yet beneath the EPS story and the confident capital return, there is a more awkward dependency that hinges on ... There's only one way to know the right time to buy, sell or hold United Therapeutics. Head to Simply Wall St's company report for the latest analysis of United Therapeutics's Fair Value. NasdaqGS:UTHR 1-Year Stock Price Chart Exploring Other Perspectives One alternate view on United Therapeutics leans hard into competition risk. The lowest analysts were already assuming revenue of about US$3.1b and earnings of roughly US$1.3b by 2029, with earnings per share near US$26.22. Those forecasts came before this EPS update, so you should expect some opinions to shift and explore how yours compares. Explore 3 other United Therapeutics fair value estimates, including one that suggests it could be worth just $687.14. Reach Your Own Conclusion Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your United Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision. See our latest analysis for United Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate United Therapeutics' overall financial health at a glance.  Looking For More Investment Ideas Beyond United Therapeutics? If the United Therapeutics story has you thinking about risk, reward and capital allocation, it can help to scan a broader set of companies that fit the kind of profile you want in your portfolio.  For investors hunting for resilient balance sheets that can support consistent decision making through different cycles, start by reviewing our list of solid balance sheet and fundamentals (23 results). If you care most about limiting downside while still staying exposed to equities, consider filtering for companies in our 29 resilient stocks with low risk scores that score well on quality and financial strength. When you want to stay early to potential re-rating stories rather than chasing crowded trades, look through the 20 high quality undiscovered gems that pair strong fundamentals with relatively low profile in the market.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2683547865","isCrawlerRequest":true}